Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
Standard
Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria. / Hoppe, Bernd; Groothoff, Jaap W; Hulton, Sally-Anne; Cochat, Pierre; Niaudet, Patrick; Kemper, Markus J.; Deschênes, George; Unwin, Robert; Milliner, Dawn.
in: NEPHROL DIAL TRANSPL, Jahrgang 26, Nr. 11, 11, 2011, S. 3609-3615.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Efficacy and safety of Oxalobacter formigenes to reduce urinary oxalate in primary hyperoxaluria.
AU - Hoppe, Bernd
AU - Groothoff, Jaap W
AU - Hulton, Sally-Anne
AU - Cochat, Pierre
AU - Niaudet, Patrick
AU - Kemper, Markus J.
AU - Deschênes, George
AU - Unwin, Robert
AU - Milliner, Dawn
PY - 2011
Y1 - 2011
N2 - Primary hyperoxaluria (PH) is a rare genetic disease, in which high urinary oxalate (Uox) cause recurrent kidney stones and/or progressive nephrocalcinosis, often followed by early end-stage renal disease, as well as extremely high plasma oxalate, systemic oxalosis and premature death. Oxalobacter formigenes, an anaerobic oxalate degrading bacterium, naturally colonizes the colon of most humans. Orally administered O. formigenes (Oxabact) was found to significantly reduce urine and plasma oxalate. We aimed to evaluate its effect and safety in a randomized, double-blind, placebo-controlled multicenter study.
AB - Primary hyperoxaluria (PH) is a rare genetic disease, in which high urinary oxalate (Uox) cause recurrent kidney stones and/or progressive nephrocalcinosis, often followed by early end-stage renal disease, as well as extremely high plasma oxalate, systemic oxalosis and premature death. Oxalobacter formigenes, an anaerobic oxalate degrading bacterium, naturally colonizes the colon of most humans. Orally administered O. formigenes (Oxabact) was found to significantly reduce urine and plasma oxalate. We aimed to evaluate its effect and safety in a randomized, double-blind, placebo-controlled multicenter study.
M3 - SCORING: Journal article
VL - 26
SP - 3609
EP - 3615
JO - NEPHROL DIAL TRANSPL
JF - NEPHROL DIAL TRANSPL
SN - 0931-0509
IS - 11
M1 - 11
ER -
